---
document_datetime: 2024-10-10 08:32:26
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/holoclar-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: holoclar-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.6367949
conversion_datetime: 2025-12-22 00:48:09.804405
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Holoclar

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IB/0067              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 08/10/2024                          | n/a                                         |                                  |                                   |
| PSUSA/10352 /202402  | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial                                            | 03/10/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | cells containing stem cells                                                                                                                                                                                                                    |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0066           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 28/06/2024 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0064             | B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer                    | 23/05/2024 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10352 /202308 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                 | 07/03/2024 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0063             | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                   | 22/02/2024 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0058              | Renewal of the marketing authorisation.                                                                                                                                                                                                        | 14/12/2023 | 22/02/2024 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated. Furthermore, the CHMP considered that, as all Specific Obligations have been fulfilled, there are no remaining grounds for the marketing authorisations to remain conditional and therefore |

<div style=\"page-break-after: always\"></div>

| recommends the granting of the MA no longer subject to Specific Obligations for Holoclar. Changes to the Product Information have been introduced, including the following: In 4.4. Special warnings and precautions for use: […] Autologous use Holoclar is intended solely for autologous use and must not, under any circumstances, be administered to other patients. Holoclar must not be administered if the information on the product labels and lot number do not match the patient's identity. […] Transmission of an infectious agent Holoclar could contain potentially infected biological material. Although Holoclar is tested for sterility and mycoplasma, a risk of transmission of infectious agents exists. Healthcare professionals administering Holoclar must, therefore, monitor patients for signs and symptoms of infections after treatment and treat appropriately, if needed. Although the risk is considered to be very low and routinely controlled in the manufacturing. […] Precautions for use A thorough evaluation of the patient should be done taking into consideration not only the clinical need of the candidate, but also the biological and pathophysiologic alterations in the wound bed environment, to define the timing of any procedure and allow the proper engraftment and growth of the stem cells of the living tissue that   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                |            |            |                        | excluded and anticipated or deferred to Holoclar implantation. Concomitant eyelids malposition, conjunctival scarring with fornix shortening, corneal anaesthesia and/or conjunctival anaesthesia or severe hypoaesthesia, pterygium and severe dry eye are potential complicating factors. When possible, Concomitant eye problems should be corrected prior to Holoclar implantation. At any of the steps of the treatment with Holoclar, topical lidocaine or anaesthetics containing adrenaline must be avoided. In 4.5. Interaction with other medicinal products and other forms of interaction: The concomitant use of topical lidocaine or anaesthetics containing adrenaline must be avoided as they reduce the colony forming efficiency.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0062           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 29/11/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| T/0060              | Transfer of Marketing Authorisation                                                                                                                                                                                                            | 25/09/2023 | 18/10/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/10352 /202302 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                 | 28/09/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IAIN/0059/G   | This was an application for a group of variations.                                                                                                                                                                                             | 22/09/2023   | 18/10/2023   | Annex II and PL   |                             |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------|
|               | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes properties of the FP                   | 22/06/2023   | n/a          |                   | IAIN/0057 do not affect the |
| IA/0054       | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                            | 20/04/2023   | n/a          |                   |                             |
| IAIN/0055     | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 17/04/2023   | n/a          |                   |                             |
| IB/0053       | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                        | 30/03/2023   | n/a          |                   |                             |

<div style=\"page-break-after: always\"></div>

| PSUSA/10352 /202208   | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                 | 16/03/2023   | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0052             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 08/03/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IAIN/0051             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                             | 20/02/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0050               | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                   | 06/02/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0048                | Renewal of the marketing authorisation.                                                                                                                                                                                                        | 10/11/2022   | 13/01/2023 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Holoclar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10352 /202202   | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                 | 29/09/2022   | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0045   | B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a approved manufacturer                                                                                                                                                                    | 29/07/2022   | n/a   | new or an already   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------|
| IAIN/0047 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes properties of the FP                                                                                                                                                 | 15/07/2022   | n/a   | do not affect the   |
| IAIN/0046 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                               | 23/06/2022   | n/a   |                     |
| IB/0044   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                  | 01/06/2022   | n/a   |                     |
| IA/0042/G | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer | 25/04/2022   | n/a   |                     |

<div style=\"page-break-after: always\"></div>

| IAIN/0041/G         | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes   | 19/04/2022   | n/a        |                                                                                                                                                                                                                                     |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10352 /202108 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/03/2022   | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                   |
| R/0039              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/10/2021   | 09/12/2021 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                     |            |            |                                  | medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Holoclar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10352 /202102 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells      | 30/09/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                |
| IB/0038             | B.I.b.z - Change in control of the AS - Other variation                                                                             | 16/09/2021 | n/a        |                                  |                                                                                                                                                                                                                                                  |
| IB/0036             | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                | 04/05/2021 | n/a        |                                  |                                                                                                                                                                                                                                                  |
| PSUSA/10352 /202008 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells      | 11/03/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                |
| IB/0035             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                        | 15/01/2021 | n/a        |                                  |                                                                                                                                                                                                                                                  |
| IB/0034             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 15/01/2021 | n/a        |                                  |                                                                                                                                                                                                                                                  |
| R/0032              | Renewal of the marketing authorisation.                                                                                             | 15/10/2020 | 07/01/2021 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this              |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                              |            |            |                                  | medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Holoclar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10352 /202002 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                               | 01/10/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                |
| T/0031              | Transfer of Marketing Authorisation                                                                                                                          | 18/05/2020 | 12/06/2020 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                  |
| IB/0029             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                             | 30/03/2020 | n/a        |                                  |                                                                                                                                                                                                                                                  |
| PSUSA/10352 /201908 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                               | 12/03/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                |
| R/0026              | Renewal of the marketing authorisation.                                                                                                                      | 14/11/2019 | 21/02/2020 | SmPC and Annex II                |                                                                                                                                                                                                                                                  |
| IA/0027             | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer | 04/10/2019 | n/a        |                                  |                                                                                                                                                                                                                                                  |
| PSUSA/10352 /201902 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                               | 05/09/2019 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IB/0023             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                      | 28/03/2019   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10352 /201808 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                               | 14/03/2019   | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0024              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                             | 22/02/2019   | 21/02/2020 | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0021              | Renewal of the marketing authorisation.                                                                                                                                                                      | 15/11/2018   | 15/01/2019 | SmPC | The CHMP having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Holoclar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10352 /201802 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                               | 06/09/2018   | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0019             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 18/05/2018   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IB/0018/G           | This was an application for a group of variations.                                                                                     | 18/05/2018   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10352 /201708 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells         | 08/03/2018   | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0017             | B.I.z - Quality change - Active substance - Other variation                                                                            | 04/01/2018   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0015              | Renewal of the marketing authorisation.                                                                                                | 12/10/2017   | 11/12/2017 | The CAT, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Holoclar, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. |
| PSUSA/10352 /201702 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells         | 28/09/2017   | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0014/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting | 28/07/2017   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of   |            |            |             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| II/0012/G | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/06/2017 | 11/12/2017 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                     | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |            |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10352 /201608 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                                                                                                | 09/03/2017 | n/a        |                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0011             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                  | 07/02/2017 | n/a        |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0008              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                       | 13/10/2016 | 08/12/2016 |                  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligation and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Holoclar, subject to the Specific Obligation and Conditions as laid down in Annex II to the Opinion. |
| N/0010              | Update of the labelling to include the unique identifier 2D barcode as per QRD template v.10 and update of the package leaflet with the revised                                                                                                                                                                               | 03/11/2016 | 11/12/2017 | Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | contact details of the local representative for France. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                       |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10352 /201602 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                                                                                                                                                                                                 | 02/09/2016 | n/a | PRAC Recommendation - maintenance |
| IA/0007/G           | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved | 23/06/2016 | n/a |                                   |
| IB/0006             | B.II.c.2.z - Change in test procedure for an excipient - Other variation                                                                                                                                                                                                                                                                                                                                                       | 10/06/2016 | n/a |                                   |
| IA/0005/G           | This was an application for a group of variations. B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability -                                                                                      | 27/05/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10352 /201508 | Periodic Safety Update EU Single assessment - ex vivo expanded autologous human corneal epithelial cells containing stem cells                                                                                                                                                          | 17/03/2016 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0003             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                            | 18/12/2015 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0001              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                 | 22/10/2015 | 10/12/2015 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Holoclar, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. |